14 recherche sur le mot-clé 'Pharmacotherapy'

Why pharmacotherapy is overused among persons with Autism Spectrum Disorders / Johnny L. MATSON in Research in Autism Spectrum Disorders, 9 (January 2015)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 9 (January 2015) . - p.34-37 Titre : Why pharmacotherapy is overused among persons with Autism Spectrum Disorders Type de document : Texte imprimé et/ou numérique Auteurs : Johnny L. MATSON, Auteur ; Matthew J. KONST, Auteur Année de publication : 2015 Article en page(s) : p.34-37 Langues : Anglais (eng) Mots-clés : Autism  Intervention  Pharmacotherapy  Psychiatry Index. décimale : PER Périodiques Résumé : Abstract Autism Spectrum Disorder (ASD) is a relatively common disorder with lifelong and lasting impairments. As a result, professionals are developing and using a host of intervention strategies. In addition to applied behavior analysis, pharmacotherapy has played a critical role in the advancements of treatment. The use of pharmacological interventions has played a central and important role in recent treatment innovations. Despite the many positive aspects of these drugs, they have often been overused. The present paper reviews many of the reasons for this phenomenon. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.10.006 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=243 [article] Why pharmacotherapy is overused among persons with Autism Spectrum Disorders [Texte imprimé et/ou numérique] / Johnny L. MATSON, Auteur ; Matthew J. KONST, Auteur . - 2015 . - p.34-37. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 9 (January 2015) . - p.34-37 Mots-clés : Autism  Intervention  Pharmacotherapy  Psychiatry Index. décimale : PER Périodiques Résumé : Abstract Autism Spectrum Disorder (ASD) is a relatively common disorder with lifelong and lasting impairments. As a result, professionals are developing and using a host of intervention strategies. In addition to applied behavior analysis, pharmacotherapy has played a critical role in the advancements of treatment. The use of pharmacological interventions has played a central and important role in recent treatment innovations. Despite the many positive aspects of these drugs, they have often been overused. The present paper reviews many of the reasons for this phenomenon. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.10.006 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=243

Consensus or chaos: Survey of prescribing practices of New Zealand child and adolescent psychiatrists for children and adolescents with autism spectrum disorder / Hiran THABREW in Research in Autism Spectrum Disorders, 74 (June 2020)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 74 (June 2020) . - p.101553 Titre : Consensus or chaos: Survey of prescribing practices of New Zealand child and adolescent psychiatrists for children and adolescents with autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Hiran THABREW, Auteur ; Anisha VISWANATHAN, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Stephanie MOOR, Auteur ; David CHINN, Auteur Article en page(s) : p.101553 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Autism  Children  Adolescents  Pharmacotherapy  Guidelines Index. décimale : PER Périodiques Résumé : Background There is limited national and international guidance on appropriate prescription of medications for children and adolescents with Autism Spectrum Disorder (ASD). In order to develop more detailed guidelines for prescribing for New Zealand children and young people with ASD, it is important to have some understanding of the nature of current prescribing and the circumstances that drive pharmacotherapy for children and young people with ASD. Method Seventy child and adolescent psychiatrists in New Zealand were electronically surveyed. Participants were asked to outline the four most common medications that they prescribed to address both core symptoms and comorbidities in children and young people with ASD. Additional questions included commonly used doses and durations of use, perceived effectiveness, adverse effects, level of confidence in prescribing and preferences for receiving up to date guidance about pharmacotherapy. Results Prescription by child and adolescent psychiatrists was most commonly undertaken for anxiety, sleep disturbance, ADHD, depression and restricted and repetitive behaviours (RRBs). The greatest difference in opinion regarding the value of medication related to the treatment of RRBs. The most commonly prescribed medications were fluoxetine, methylphenidate, melatonin, risperidone, quetiapine and clonidine. A range of non-pharmacological therapies were also described. Conclusions Although there appears to be general agreement between New Zealand child and adolescent psychiatrists regarding prescribing for children and young people with ASD, current clinical practice is not adequately informed by existing guidelines. Better dissemination of national guidelines incorporating both contemporary international evidence regarding medication efficacy and locally developed algorithms based on clinician consensus would be useful. En ligne : https://doi.org/10.1016/j.rasd.2020.101553 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=422 [article] Consensus or chaos: Survey of prescribing practices of New Zealand child and adolescent psychiatrists for children and adolescents with autism spectrum disorder [Texte imprimé et/ou numérique] / Hiran THABREW, Auteur ; Anisha VISWANATHAN, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Stephanie MOOR, Auteur ; David CHINN, Auteur . - p.101553. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 74 (June 2020) . - p.101553 Mots-clés : Autism spectrum disorder  Autism  Children  Adolescents  Pharmacotherapy  Guidelines Index. décimale : PER Périodiques Résumé : Background There is limited national and international guidance on appropriate prescription of medications for children and adolescents with Autism Spectrum Disorder (ASD). In order to develop more detailed guidelines for prescribing for New Zealand children and young people with ASD, it is important to have some understanding of the nature of current prescribing and the circumstances that drive pharmacotherapy for children and young people with ASD. Method Seventy child and adolescent psychiatrists in New Zealand were electronically surveyed. Participants were asked to outline the four most common medications that they prescribed to address both core symptoms and comorbidities in children and young people with ASD. Additional questions included commonly used doses and durations of use, perceived effectiveness, adverse effects, level of confidence in prescribing and preferences for receiving up to date guidance about pharmacotherapy. Results Prescription by child and adolescent psychiatrists was most commonly undertaken for anxiety, sleep disturbance, ADHD, depression and restricted and repetitive behaviours (RRBs). The greatest difference in opinion regarding the value of medication related to the treatment of RRBs. The most commonly prescribed medications were fluoxetine, methylphenidate, melatonin, risperidone, quetiapine and clonidine. A range of non-pharmacological therapies were also described. Conclusions Although there appears to be general agreement between New Zealand child and adolescent psychiatrists regarding prescribing for children and young people with ASD, current clinical practice is not adequately informed by existing guidelines. Better dissemination of national guidelines incorporating both contemporary international evidence regarding medication efficacy and locally developed algorithms based on clinician consensus would be useful. En ligne : https://doi.org/10.1016/j.rasd.2020.101553 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=422

Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis / R. RODRIGUES in Journal of Child Psychology and Psychiatry, 62-6 (June 2021)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 62-6 (June 2021) . - p.680-700 Titre : Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis Type de document : Texte imprimé et/ou numérique Auteurs : R. RODRIGUES, Auteur ; Meng-Chuan LAI, Auteur ; A. BESWICK, Auteur ; D. A. GORMAN, Auteur ; Evdokia ANAGNOSTOU, Auteur ; P. SZATMARI, Auteur ; K. K. ANDERSON, Auteur ; Stephanie H. AMEIS, Auteur Article en page(s) : p.680-700 Langues : Anglais (eng) Mots-clés : Adolescent  Atomoxetine Hydrochloride/therapeutic use  Attention Deficit Disorder with Hyperactivity/drug therapy  Autism Spectrum Disorder/drug therapy  Central Nervous System Stimulants/adverse effects  Child  Guanfacine  Humans  Methylphenidate/adverse effects  Adhd  Attention-deficit/hyperactivity disorder  alpha-2 agonists  antipsychotics  atomoxetine  autism spectrum disorder  bupropion  hyperactivity  impulsivity  inattention  modafinil.  pervasive developmental disorder  pharmacotherapy  stimulants  tricyclic antidepressants  venlafaxine Index. décimale : PER Périodiques Résumé : BACKGROUND: Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD). The aim of this systematic review and meta-analysis was to (a) evaluate the efficacy and safety of pharmacotherapy for the treatment of ADHD symptoms in ASD and (b) distil findings for clinical translation. METHODS: We searched electronic databases and clinical trial registries (1992 onwards). We selected randomized controlled trials conducted in participants <25 years of age, diagnosed with ASD that evaluated ADHD outcomes (hyperactivity/impulsivity and inattention) following treatment with stimulants (methylphenidate or amphetamines), atomoxetine, alpha-2 adrenergic receptor agonists, antipsychotics, tricyclic antidepressants, bupropion, modafinil, venlafaxine, or a combination, in comparison with placebo, any of the listed medications, or behavioral therapies. Data were pooled using a random-effects model. RESULTS: Twenty-five studies (4 methylphenidate, 4 atomoxetine, 1 guanfacine, 14 antipsychotic, 1 venlafaxine, and 1 tianeptine) were included. Methylphenidate reduced hyperactivity (parent-rated: standardized mean difference [SMD] = -.63, 95%CI = -.95,-.30; teacher-rated: SMD = -.81, 95%CI = -1.43,-.19) and inattention (parent-rated: SMD = -.36, 95%CI = -.64,-.07; teacher-rated: SMD = -.30, 95%CI = -.49,-.11). Atomoxetine reduced inattention (parent-rated: SMD = -.54, 95%CI = -.98,-.09; teacher/investigator-rated: SMD = -0.38, 95%CI = -0.75, -0.01) and parent-rated hyperactivity (parent-rated: SMD = -.49, 95%CI = -.76,-.23; teacher-rated: SMD = -.43, 95%CI = -.92, .06). Indirect evidence for significant reductions in hyperactivity with second-generation antipsychotics was also found. Quality of evidence for all interventions was low/very low. Methylphenidate was associated with a nonsignificant elevated risk of dropout due to adverse events. CONCLUSIONS: Direct pooled evidence supports the efficacy and tolerability of methylphenidate or atomoxetine for treatment of ADHD symptoms in children and youth with ASD. The current review highlights the efficacy of standard ADHD pharmacotherapy for treatment of ADHD symptoms in children and youth with ASD. Consideration of the benefits weighed against the limitations of safety/efficacy data and lack of data evaluating long-term continuation is undertaken to help guide clinical decision-making regarding treatment of co-occurring ADHD symptoms in children and youth with ASD. En ligne : http://dx.doi.org/10.1111/jcpp.13305 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455 [article] Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis [Texte imprimé et/ou numérique] / R. RODRIGUES, Auteur ; Meng-Chuan LAI, Auteur ; A. BESWICK, Auteur ; D. A. GORMAN, Auteur ; Evdokia ANAGNOSTOU, Auteur ; P. SZATMARI, Auteur ; K. K. ANDERSON, Auteur ; Stephanie H. AMEIS, Auteur . - p.680-700. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 62-6 (June 2021) . - p.680-700 Mots-clés : Adolescent  Atomoxetine Hydrochloride/therapeutic use  Attention Deficit Disorder with Hyperactivity/drug therapy  Autism Spectrum Disorder/drug therapy  Central Nervous System Stimulants/adverse effects  Child  Guanfacine  Humans  Methylphenidate/adverse effects  Adhd  Attention-deficit/hyperactivity disorder  alpha-2 agonists  antipsychotics  atomoxetine  autism spectrum disorder  bupropion  hyperactivity  impulsivity  inattention  modafinil.  pervasive developmental disorder  pharmacotherapy  stimulants  tricyclic antidepressants  venlafaxine Index. décimale : PER Périodiques Résumé : BACKGROUND: Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD). The aim of this systematic review and meta-analysis was to (a) evaluate the efficacy and safety of pharmacotherapy for the treatment of ADHD symptoms in ASD and (b) distil findings for clinical translation. METHODS: We searched electronic databases and clinical trial registries (1992 onwards). We selected randomized controlled trials conducted in participants <25 years of age, diagnosed with ASD that evaluated ADHD outcomes (hyperactivity/impulsivity and inattention) following treatment with stimulants (methylphenidate or amphetamines), atomoxetine, alpha-2 adrenergic receptor agonists, antipsychotics, tricyclic antidepressants, bupropion, modafinil, venlafaxine, or a combination, in comparison with placebo, any of the listed medications, or behavioral therapies. Data were pooled using a random-effects model. RESULTS: Twenty-five studies (4 methylphenidate, 4 atomoxetine, 1 guanfacine, 14 antipsychotic, 1 venlafaxine, and 1 tianeptine) were included. Methylphenidate reduced hyperactivity (parent-rated: standardized mean difference [SMD] = -.63, 95%CI = -.95,-.30; teacher-rated: SMD = -.81, 95%CI = -1.43,-.19) and inattention (parent-rated: SMD = -.36, 95%CI = -.64,-.07; teacher-rated: SMD = -.30, 95%CI = -.49,-.11). Atomoxetine reduced inattention (parent-rated: SMD = -.54, 95%CI = -.98,-.09; teacher/investigator-rated: SMD = -0.38, 95%CI = -0.75, -0.01) and parent-rated hyperactivity (parent-rated: SMD = -.49, 95%CI = -.76,-.23; teacher-rated: SMD = -.43, 95%CI = -.92, .06). Indirect evidence for significant reductions in hyperactivity with second-generation antipsychotics was also found. Quality of evidence for all interventions was low/very low. Methylphenidate was associated with a nonsignificant elevated risk of dropout due to adverse events. CONCLUSIONS: Direct pooled evidence supports the efficacy and tolerability of methylphenidate or atomoxetine for treatment of ADHD symptoms in children and youth with ASD. The current review highlights the efficacy of standard ADHD pharmacotherapy for treatment of ADHD symptoms in children and youth with ASD. Consideration of the benefits weighed against the limitations of safety/efficacy data and lack of data evaluating long-term continuation is undertaken to help guide clinical decision-making regarding treatment of co-occurring ADHD symptoms in children and youth with ASD. En ligne : http://dx.doi.org/10.1111/jcpp.13305 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455

Reduced Serotonin Receptor Subtypes in a Limbic and a Neocortical Region in Autism / Adrian OBLAK in Autism Research, 6-6 (December 2013)  

Public ISBD [article]  inAutism Research > 6-6 (December 2013) . - p.571-583 Titre : Reduced Serotonin Receptor Subtypes in a Limbic and a Neocortical Region in Autism Type de document : Texte imprimé et/ou numérique Auteurs : Adrian OBLAK, Auteur ; Terrell T. GIBBS, Auteur ; Gene J. BLATT, Auteur Année de publication : 2013 Article en page(s) : p.571-583 Langues : Anglais (eng) Mots-clés : autism  serotonin  5-HT1A receptors  5-HT2A receptors  5-HT transporters  pharmacotherapy  selective serotonin reuptake inhibitors (SSRI) Index. décimale : PER Périodiques Résumé : Autism is a behaviorally defined, neurological disorder with symptom onset before the age of 3. Abnormalities in social-emotional behaviors are a core deficit in autism, and are characterized by impaired reciprocal–social interaction, lack of facial expressions, and the inability to recognize familiar faces. The posterior cingulate cortex (PCC) and fusiform gyrus (FG) are two regions within an extensive limbic-cortical network that contribute to social-emotional behaviors. Evidence indicates that changes in brains of individuals with autism begin prenatally. Serotonin (5-HT) is one of the earliest expressed neurotransmitters, and plays an important role in synaptogenesis, neurite outgrowth, and neuronal migration. Abnormalities in 5-HT systems have been implicated in several psychiatric disorders, including autism, as evidenced by immunology, imaging, genetics, pharmacotherapy, and neuropathology. Although information is known regarding peripheral 5-HT in autism, there is emerging evidence that 5-HT systems in the central nervous system, including various 5-HT receptor subtypes and transporters, are affected in autism. The present study demonstrated significant reductions in 5-HT1A receptor-binding density in superficial and deep layers of the PCC and FG, and in the density of 5-HT2A receptors in superficial layers of the PCC and FG. A significant reduction in the density of serotonin transporters (5-HTT) was also found in the deep layers of the FG, but normal levels were demonstrated in both layers of the PCC and superficial layers of the FG. This study provides potential substrates for decreased 5-HT modulation/innervation in the autism brain, and implicate two 5-HT receptor subtypes as potential neuromarkers for novel or existing pharmacotherapies. En ligne : http://dx.doi.org/10.1002/aur.1317 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=221 [article] Reduced Serotonin Receptor Subtypes in a Limbic and a Neocortical Region in Autism [Texte imprimé et/ou numérique] / Adrian OBLAK, Auteur ; Terrell T. GIBBS, Auteur ; Gene J. BLATT, Auteur . - 2013 . - p.571-583. Langues : Anglais (eng) in Autism Research > 6-6 (December 2013) . - p.571-583 Mots-clés : autism  serotonin  5-HT1A receptors  5-HT2A receptors  5-HT transporters  pharmacotherapy  selective serotonin reuptake inhibitors (SSRI) Index. décimale : PER Périodiques Résumé : Autism is a behaviorally defined, neurological disorder with symptom onset before the age of 3. Abnormalities in social-emotional behaviors are a core deficit in autism, and are characterized by impaired reciprocal–social interaction, lack of facial expressions, and the inability to recognize familiar faces. The posterior cingulate cortex (PCC) and fusiform gyrus (FG) are two regions within an extensive limbic-cortical network that contribute to social-emotional behaviors. Evidence indicates that changes in brains of individuals with autism begin prenatally. Serotonin (5-HT) is one of the earliest expressed neurotransmitters, and plays an important role in synaptogenesis, neurite outgrowth, and neuronal migration. Abnormalities in 5-HT systems have been implicated in several psychiatric disorders, including autism, as evidenced by immunology, imaging, genetics, pharmacotherapy, and neuropathology. Although information is known regarding peripheral 5-HT in autism, there is emerging evidence that 5-HT systems in the central nervous system, including various 5-HT receptor subtypes and transporters, are affected in autism. The present study demonstrated significant reductions in 5-HT1A receptor-binding density in superficial and deep layers of the PCC and FG, and in the density of 5-HT2A receptors in superficial layers of the PCC and FG. A significant reduction in the density of serotonin transporters (5-HTT) was also found in the deep layers of the FG, but normal levels were demonstrated in both layers of the PCC and superficial layers of the FG. This study provides potential substrates for decreased 5-HT modulation/innervation in the autism brain, and implicate two 5-HT receptor subtypes as potential neuromarkers for novel or existing pharmacotherapies. En ligne : http://dx.doi.org/10.1002/aur.1317 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=221

Relative immaturity and ADHD: findings from nationwide registers, parent- and self-reports / Linda HALLDNER in Journal of Child Psychology and Psychiatry, 55-8 (August 2014)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 55-8 (August 2014) . - p.897-904 Titre : Relative immaturity and ADHD: findings from nationwide registers, parent- and self-reports Type de document : Texte imprimé et/ou numérique Auteurs : Linda HALLDNER, Auteur ; Annika TILLANDER, Auteur ; Cecilia LUNDHOLM, Auteur ; Marcus BOMAN, Auteur ; Niklas LANGSTROM, Auteur ; Henrik LARSSON, Auteur ; Paul LICHTENSTEIN, Auteur Article en page(s) : p.897-904 Langues : Anglais (eng) Mots-clés : ADHD  child development  pharmacotherapy  epidemiological studies Index. décimale : PER Périodiques Résumé : Background We addressed if immaturity relative to peers reflected in birth month increases the likelihood of ADHD diagnosis and treatment. Methods We linked nationwide Patient and Prescribed Drug Registers and used prospective cohort and nested case–control designs to study 6–69 year-old individuals in Sweden from July 2005 to December 2009 (Cohort 1). Cohort 1 included 56,263 individuals diagnosed with ADHD or ever used prescribed ADHD-specific medication. Complementary population-representative cohorts provided DSM-IV ADHD symptom ratings; parent-reported for 10,760 9-year-old twins born 1995–2000 from the CATSS study (Cohort 2) and self-reported for 6,970 adult twins age 20–47 years born 1959–1970 from the STAGE study (Cohort 3). We calculated odds ratios (OR:s) for ADHD across age for individuals born in November/December compared to January/February (Cohort 1). ADHD symptoms in Cohorts 2 and 3 were studied as a function of calendar birth month. Results ADHD diagnoses and medication treatment were both significantly more common in individuals born in November/December versus January/February; peaking at ages 6 (OR: 1.8; 95% CI: 1.5–2.2) and 7 years (OR: 1.6; 95% CI: 1.3–1.8) in the Patient and Prescribed Drug Registers, respectively. We found no corresponding differences in parent- or self-reported ADHD symptoms by calendar birth month. Conclusion Relative immaturity compared to class mates might contribute to ADHD diagnosis and pharmacotherapy despite absence of parallel findings in reported ADHD symptom loads by relative immaturity. Increased clinical awareness of this phenomenon may be warranted to decrease risk for imprecise diagnostics and treatment. We speculate that flexibility regarding age at school start according to individual maturity could reduce developmentally inappropriate demands on children and improve the precision of ADHD diagnostic practice and pharmacological treatment. En ligne : http://dx.doi.org/10.1111/jcpp.12229 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=237 [article] Relative immaturity and ADHD: findings from nationwide registers, parent- and self-reports [Texte imprimé et/ou numérique] / Linda HALLDNER, Auteur ; Annika TILLANDER, Auteur ; Cecilia LUNDHOLM, Auteur ; Marcus BOMAN, Auteur ; Niklas LANGSTROM, Auteur ; Henrik LARSSON, Auteur ; Paul LICHTENSTEIN, Auteur . - p.897-904. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 55-8 (August 2014) . - p.897-904 Mots-clés : ADHD  child development  pharmacotherapy  epidemiological studies Index. décimale : PER Périodiques Résumé : Background We addressed if immaturity relative to peers reflected in birth month increases the likelihood of ADHD diagnosis and treatment. Methods We linked nationwide Patient and Prescribed Drug Registers and used prospective cohort and nested case–control designs to study 6–69 year-old individuals in Sweden from July 2005 to December 2009 (Cohort 1). Cohort 1 included 56,263 individuals diagnosed with ADHD or ever used prescribed ADHD-specific medication. Complementary population-representative cohorts provided DSM-IV ADHD symptom ratings; parent-reported for 10,760 9-year-old twins born 1995–2000 from the CATSS study (Cohort 2) and self-reported for 6,970 adult twins age 20–47 years born 1959–1970 from the STAGE study (Cohort 3). We calculated odds ratios (OR:s) for ADHD across age for individuals born in November/December compared to January/February (Cohort 1). ADHD symptoms in Cohorts 2 and 3 were studied as a function of calendar birth month. Results ADHD diagnoses and medication treatment were both significantly more common in individuals born in November/December versus January/February; peaking at ages 6 (OR: 1.8; 95% CI: 1.5–2.2) and 7 years (OR: 1.6; 95% CI: 1.3–1.8) in the Patient and Prescribed Drug Registers, respectively. We found no corresponding differences in parent- or self-reported ADHD symptoms by calendar birth month. Conclusion Relative immaturity compared to class mates might contribute to ADHD diagnosis and pharmacotherapy despite absence of parallel findings in reported ADHD symptom loads by relative immaturity. Increased clinical awareness of this phenomenon may be warranted to decrease risk for imprecise diagnostics and treatment. We speculate that flexibility regarding age at school start according to individual maturity could reduce developmentally inappropriate demands on children and improve the precision of ADHD diagnostic practice and pharmacological treatment. En ligne : http://dx.doi.org/10.1111/jcpp.12229 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=237

Commentary: Using QbTest for monitoring pharmacological treatment response in ADHD - are we there yet? / Alessio BELLATO ; Valeria PARLATINI ; Madeleine J. GROOM ; Charlotte L. HALL ; Chris HOLLIS ; Emily SIMONOFF ; Anita THAPAR ; Samuele CORTESE in Journal of Child Psychology and Psychiatry, 66-2 (February 2025)  

Permalink

Editorial: Common factors in the art of healing / B. S. PETERSON in Journal of Child Psychology and Psychiatry, 60-9 (September 2019)  

Permalink

Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay / Ozlem BOZDAGI in Molecular Autism, (April 2013)  

Permalink

Multidisciplinary Assessment and Treatment of Self-Injurious Behavior in Autism Spectrum Disorder and Intellectual Disability: Integration of Psychological and Biological Theory and Approach / Noha F. MINSHAWI in Journal of Autism and Developmental Disorders, 45-6 (June 2015)  

Permalink

National prescribing rates and polypharmacy for children and young people in New Zealand with and without autism spectrum disorder / Nicholas J. BOWDEN in Research in Autism Spectrum Disorders, 78 (October 2020)  

Permalink